Aug 12 (Reuters) - Noxopharm Ltd (NOX) : NOXOPHARM - REPORTED PRE-CLINICAL DATA CONFIRMING A SURVIVAL BENEFIT OF ADDING VEYONDA TO 177LUTETIUM-PSMA-617 TREATMENT IN PROSTATE CANCER